X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Abbott India - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs ABBOTT INDIA - Comparison Results

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA ABBOTT INDIA ALEMBIC PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 28.6 43.5 65.6% View Chart
P/BV x 6.5 10.9 59.9% View Chart
Dividend Yield % 0.7 0.6 117.1%  

Financials

 ALEMBIC PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
ABBOTT INDIA
Mar-16
ALEMBIC PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs7926,015 13.2%   
Low Rs4433,707 12.0%   
Sales per share (Unadj.) Rs167.01,236.9 13.5%  
Earnings per share (Unadj.) Rs38.2122.2 31.2%  
Cash flow per share (Unadj.) Rs42.0129.0 32.6%  
Dividends per share (Unadj.) Rs4.0035.00 11.4%  
Dividend yield (eoy) %0.60.7 90.0%  
Book value per share (Unadj.) Rs84.9521.2 16.3%  
Shares outstanding (eoy) m188.5221.25 887.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.73.9 94.1%   
Avg P/E ratio x16.239.8 40.7%  
P/CF ratio (eoy) x14.737.7 39.0%  
Price / Book Value ratio x7.39.3 78.0%  
Dividend payout %10.528.6 36.6%   
Avg Mkt Cap Rs m116,383103,296 112.7%   
No. of employees `000NA3.0 0.0%   
Total wages/salary Rs m4,2143,370 125.0%   
Avg. sales/employee Rs ThNM8,891.8-  
Avg. wages/employee Rs ThNM1,140.0-  
Avg. net profit/employee Rs ThNM878.3-  
INCOME DATA
Net Sales Rs m31,48726,284 119.8%  
Other income Rs m55504 10.9%   
Total revenues Rs m31,54226,789 117.7%   
Gross profit Rs m10,0603,665 274.5%  
Depreciation Rs m722144 500.1%   
Interest Rs m378 454.3%   
Profit before tax Rs m9,3564,017 232.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1601,421 152.0%   
Profit after tax Rs m7,1942,596 277.1%  
Gross profit margin %31.913.9 229.1%  
Effective tax rate %23.135.4 65.3%   
Net profit margin %22.89.9 231.3%  
BALANCE SHEET DATA
Current assets Rs m15,06614,446 104.3%   
Current liabilities Rs m7,6744,725 162.4%   
Net working cap to sales %23.537.0 63.5%  
Current ratio x2.03.1 64.2%  
Inventory Days Days6751 130.3%  
Debtors Days Days4120 207.7%  
Net fixed assets Rs m8,2371,113 740.2%   
Share capital Rs m377213 177.4%   
"Free" reserves Rs m15,41610,808 142.6%   
Net worth Rs m16,00511,076 144.5%   
Long term debt Rs m00-   
Total assets Rs m24,59416,241 151.4%  
Interest coverage x255.2497.0 51.4%   
Debt to equity ratio x00-  
Sales to assets ratio x1.31.6 79.1%   
Return on assets %29.416.0 183.3%  
Return on equity %44.923.4 191.8%  
Return on capital %58.736.3 161.5%  
Exports to sales %55.70.6 9,066.0%   
Imports to sales %10.412.6 82.5%   
Exports (fob) Rs m17,551162 10,860.6%   
Imports (cif) Rs m3,2833,322 98.8%   
Fx inflow Rs m17,811268 6,645.7%   
Fx outflow Rs m5,3183,927 135.4%   
Net fx Rs m12,493-3,659 -341.4%   
CASH FLOW
From Operations Rs m9,3042,514 370.0%  
From Investments Rs m-3,105-800 388.3%  
From Financial Activity Rs m-1,959-803 244.0%  
Net Cashflow Rs m4,240912 465.0%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 2.9 7.9 36.7%  
FIIs % 9.1 0.1 9,100.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 17.1 81.3%  
Shareholders   49,328 18,270 270.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   ALEMBIC LTD  SUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  AUROBINDO PHARMA  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Feb 19, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - UNICHEM LAB COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS